Anasys operates as an independent brand with full ownership of its technology, quality systems, and customer relationships. Governance is not a bureaucratic overlay — it is the framework that ensures every strategic decision, from product architecture to market expansion, serves one fixed reference point: patient safety.
Since its founding in 2009, Anasys has maintained a lean but rigorous governance structure. Shareholders appoint a Board of Directors responsible for strategic oversight. The Board brings together expertise in diagnostic engineering, clinical laboratory operations, regulatory affairs, and international business — ensuring that product decisions are grounded in clinical reality, not commercial convenience.
Specialized committees operate within the Board, scaled to the size of the company:
Audit Committee Oversees financial reporting, internal controls, and external audits. Financial integrity reflects the same discipline required in diagnostic integrity.
Nomination Committee Maintains the right balance of skills and independence on the Board and identifies members who understand clinical diagnostics.
Compensation Committee Aligns executive rewards with long term value creation, including system uptime, customer satisfaction, and accuracy metrics.
The Board appoints executive officers to execute the strategic plan. Internal bodies support them, including a Quality and Compliance Committee that reviews nonconformities, corrective actions, and regulatory findings, and a Risk and Post Market Surveillance Panel that manages supplier audits, field corrections, and adverse event monitoring. An independent Internal Audit function reports directly to the Audit Committee.
Headquartered in Shenzhen, Anasys applies these governance principles across all markets and its vertically integrated network. A lean structure does not weaken governance; it ensures that every decision is visible, every risk is owned, and every leader is accountable.
Anasys is led by its founding team and an executive management group, with strategic direction reviewed by a Board of Directors. The Board’s primary function is to ensure that longterm strategy — product portfolio, technology roadmaps, market expansion — remains aligned with core values and patient safety.
The Board delegates specific oversight to a Quality & Compliance Committee, which reviews nonconformities, corrective and preventive actions (CAPA), regulatory inspection findings, and postmarket surveillance data. The committee meets quarterly and reports directly to the full Board. For a company of Anasys’s size and focus, this ensures that quality and safety never become subordinate to commercial pressure.
Three anchors guide every decision: transparency, accountability, and unwavering prioritization of patient safety. Design reviews, supplier selection, field correction decisions, and postmarket surveillance are all documented and auditable. Accountability extends to the laboratory professionals and patients who depend on every result.
Anasys operates under a certified quality management system compliant with ISO 13485 — the same standard required of medical device manufacturers worldwide. The risk management process follows ISO 14971, with specific attention to diagnostic hazards: reagent stability, sample integrity, carryover contamination, and software errors.
NMPA registration in China, CE marking for select products (under IVDR), and additional regional registrations are maintained directly by Anasys. Active surveillance of regulatory changes in China, the EU, and other target markets is continuous. Compliance is not a onetime audit — it is daily discipline: document control, training, process adherence.
Because Anasys vertically integrates its technology and manufacturing resources, the company exercises direct control over supplier qualifications. A rigorous supplier qualification program includes annual onsite audits, focusing on adherence to ISO 13485 and applicable IVD standards (ISO 15197 for glucose meters, CLSI guidelines for reagent performance). No component, reagent lot, or assembly enters an Anasys system without passing internal verification.
We view laboratory professionals, distributors, regulators, employees, and collaborative partners as essential stakeholders. Our engagement takes practical forms: user feedback sessions during beta testing and protocol development, postinstallation surveys sent to every new site, open communication channels for distributors to report market intelligence and field issues, and regular quality and performance reviews with our production centers. We are not a distant, faceless entity. We are an accessible team, and we listen — because listening is the fastest route to meaningful improvement.
Subscribe to access specialized product classifications and tailored laboratory solutions. Enhance your operational efficiency with our systematic intelligence.
© Nortek HealthCare Group Ltd., 2009-2026. All rights reserved.
This site operates under the laws of the People's Republic of China. Your access and use constitute acceptance of these Terms of Use and our Privacy Policy. All content is governed by our Privacy Notice. For details or inquiries, please Contact Us or use the site's search function.
